Method of treating allergic rhinitis of domestic etiology

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to allergology, and can be applied for treatment of allergic rhinitis of domestic etiology. For this purpose in treatment included is allergen-specific immunotherapy with sublingual introduction of cause-significant allergen. Simultaneously hirudotherapy with application of medical leech on skin in region of oral cavity bottom projection is carried out. Procedures are carried out 2 times per week, starting from 0.1 ml 10-6 degree of dissolving of cause-significant allergen and bringing up to 0.5 ml of undissolved allergen, which after that is introduced 1 time per 2 weeks during 3 years.

EFFECT: invention allows to increase treatment efficiency due to increase of cause-significant allergen penetration into system of organs of mucosal immunity of upper airways.

1 ex

 

The invention relates to medicine, namely to Allergology, and can be used in the treatment of allergic rhinitis household etiology, flowing year-round.

Currently, there is no doubt that the position that the most effective method of treatment of allergic diseases with uncontrolled sensitization is allergen immunotherapy cause significant allergens, leading to the reduction of state-specific hypersensitivity and the formation of immune tolerance.

There is a method of treatment of persisting (year-round) allergic rhinitis household etiology by allergen specific immunotherapy, consisting of subcutaneous injection cause significant allergens (allergen) in gradually increasing doses. The disadvantage of this method is low efficiency and technical difficulties associated with the high cost of the time of the doctor-allergist and patient, as well as the possibility of complications such as anaphylaxis (Bousquet j, Lockey R., Mailing H.J., Alvarez-Cuesta E., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Wold Healtg Organization. American academy of Allergy, Asthma and Immunology // Ann. Allergy Astgma Immunol. - 1998. - Vol.81. - P.401-405 (PMID: 9860031).

Closest to the claimed invention, the achieved result is a method of treatment of allergic rhinitis household etiology,consisting of sublingual application of cause-significant household allergens: house dust, microclima and allergens library of dust (Pajno, G., D. Peroni, Boner A. Efficacy of sublingual immunotherapy in asthma and eczema // Chem. Immunol. Allrgy. - 2003. Vol.82. - P.77-88.).

The disadvantage of this method is its low efficiency due to the rapid elimination of the drug from the mucous membranes of the mouth, just not deep enough penetration cause significant allergens in the system mucosal lymphoid formations associated with the upper airway due to disorders of microcirculation caused by the primary disease.

The authors proposed a method for the treatment of allergic rhinitis household etiology that do not require a visit to the doctor-allergist and eliminating the risk of anaphylaxis to effectively stop the allergic process in the nasal cavity and conductive to long-term and sustained remission of the disease.

The technical result of the proposed method is to increase the effectiveness of treatment of allergic rhinitis by improving the "offering" causal-significant allergens, increased their penetration in the system of bodies of mucosal immunity in the upper respiratory tract during step therapy scheme proposed by the authors.

The technical result is achieved by the fact that simultaneously with the sublingual administration of the drug cause significant allergen (allergen) is avodat hirudotherapy in the form of imposition of medical leeches on the skin in the area of projection of the floor of mouth 2 times a week from 0.1 ml of 10 -6the dilution cause significant allergen to 0.5 ml of undiluted serum, input 1 every 2 weeks for 3 years.

The method is as follows.

By the present method causal-significant allergens house dust, microclima and allergens library dust sublingual applied on a background of treatment that leads to their better penetration into peripheral lymphoid education, and therefore better "present" allergenic load and more rapid and reliable relief of allergic rhinitis, without the risk of systemic allergic reactions. Home sensitization is diagnosed when the results are at least 3 stages of the four support points diagnose allergies: allergic history, skin testing, provocative tests, and laboratory studies of specific antibodies of immunoglobulin E.

Patients allergic rhinitis household etiology sublingual enter a "guilty" allergen (allergen) - house dust and/or library dust and/or microclima 2 times a week, starting with the 0.1 ml of 10-6the dilution of the allergen, and is brought to 0.5 ml of undiluted serum, which then assign 1 to every 2 weeks for 3 years. Simultaneously with sublingual introduction of the allergen on the skin in the region the particular projection of the floor of mouth impose one medical leech to inadvertent separation, after bleeding the wound is closed with a sterile swab. Expose haemolymph is from 20 to 50 ml.

Clinical example

Svetlana, 25 years.

Clinical diagnosis: allergic rhinitis, year-round for home sensitization (dermatophagoides).

Complained of a violation of nasal breathing, sneezing, serous discharge and itching in the nose, increasing the premises in the afternoon and at night and decreasing on the street. Got sick about 3 years ago. The disease: SARS - rare.

The General condition is satisfactory, health does not suffer. Skin, clean skin color. Nasal breathing is impaired, the mucous membranes are swollen, blood has a grayish tint in the nasal cavity mucous-serous discharge. The back wall of the pharynx hyperemic, it can be seen hyperplastic follicles.

When skin scratch testing is defined positive (++) test with microclean (dermatophagoides), provocative nasal test with the same allergen positive.

The patient through daily use antihistamine drug cetirizine (Zyrtec) and a nasal steroid fluticasone (Flixonase) after 1 month was achieved pharmacological remission (control rhinitis), against which started sublingual allergen-specific therapy (ASIT) allege the ohms of microclima (dermatophagoides) with a dose of 0.1 ml of 10 -6the dilution 2 times a week and brought to 0.5 ml of undiluted drug allergen entered 1 time in 2 weeks. During ASIT patient were correlated with health leech on the skin projection of the bottom of the mouth to the spontaneous separation. Bleeding wound was closed with a sterile cotton swab.

After 6 months of therapy after cancelled antihistamine medication and topical steroid, clinical manifestations of rhinitis, the patient was absent. By the present method ASIT was carried out for 3 years and was accompanied by sustained clinical remission of the disease.

Authors ' method for the treatment of allergic rhinitis household etiology makes it possible to arrest the clinical manifestations of this disease. The advantage of the proposed method over the known is that the inventive method allows in a short time effectively arrest the symptoms of allergic rhinitis without the risk of systemic allergic reactions and complications.

The method of treatment of allergic rhinitis household etiology, including sublingual application of the allergen-specific therapy, characterized in that simultaneously with the introduction of the drug cause significant allergen carry out occupational therapy in the form of imposition of medical leeches on the skin pokr is you in the area of projection of the bottom of the oral cavity; these procedures carried out 2 times a week from 0.1 ml of 10-6the dilution cause significant allergen to 0.5 ml not diluted allergen, input 1 every 2 weeks for 3 years.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to allergology, and can be used for treating angioedemas. For this purpose introduced are antihistamine preparations, membrane-stabilisers, as well as pulmicort as glucocorticosteroid preparation. Pulmicort is introduced in amount 10 drops per 2 ml of physiological solution by inhalations through nebuliser during 3 minutes. Introduction of pulmicort is carried out daily during 1-3 days.

EFFECT: invention allows fast reduction of gullet and pharynx angioedemas due to direct impact on mucous membranes by said glucocorticosteroid in dose and mode of introduction specially designed for this purpose.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to new compounds of formula I in the form of salt where J means a C1-C2 alkylene; R1 means cyclopentane, cyclohexyl, phenyl or thiophenes; R2 means hydroxy; R3 means a cyclopentane, cyclohexyl, phenyl or thiophenes; with R1 and R3 are not identical, or -CR1R2R3 together form a group of the formula , where Ra means a chemical bond, and Rb means hydroxy; R4 means methyl; R5 means C1 alkyl substituted with -CO-NH-R6; R6 means 5- or 6-membered heterocyclic group that contains in a cycle at least one heteroatom selected from nitrogen, oxygen and sulfur; or J means C1-C2 alkylene; R1 and R3 both mean phenyl; R2 means hydroxy; R4 means methyl, R5 means C1 alkyl substituted with -CO-NH-R9; and R9 means 5- or 6-membered heterocyclic group that contains in a cycle at least one heteroatom selected from nitrogen, oxygen and sulfur. The invention also refers to pharmaceutical composition, to application of compound according to any of clauses 1-3, as well as to method for obtaining a compound of formula I according to clause 1.

EFFECT: obtaining new biologically active compounds having antagonistic activity against muscarinic receptor M3.

7 cl, 21 ex

FIELD: chemistry.

SUBSTANCE: novel 1,2,4-triazole derivatives - protein kinase inhibitors of formula (I) are described, where X - N; Y - CH2, NH, NR or 0; R1 and R2 each independently denote hydrogen; R3 is phenyl, substituted with -CN, 6-member heteroaryl containing 1-2 N atoms, possibly substituted with a 7-member heterocyclyl containing 2 nitrogen atoms, which in turn is substituted with C1-6alkylcarbonyl; R4 is hydrogen; R5 is hydrogen or -CN; and R is a C1-6alkyl group, C1-6alkylcarbonyl group substituted with -CN, or a C3-6cycloalkyl group, a method of inhibiting FLT-3 or c-KIT protein kinase.

EFFECT: obtaining novel compounds and their use in making a medicinal agent for treating or relieving acute myelogenic leucosis.

11 cl, 1 tbl, 13 ex

FIELD: medicine, veterinary science.

SUBSTANCE: agent for treating inflammatory and allergic skin disease in cats and dogs contains Polcortolon as a glucocorticosteroid, Levomycetin and Metronidazole as an antibiotic, excipients - lidocaine hydrochloride, dimethyl formamide, dimethyl sulphoxide, isopropyl alcohol and polyethylene glycol 400, additionally contains calendula extract and Metronidazole, in the following ratio, wt %: Polcortolon 0.01-3.0; Levomycetin 0.1-3.0; lidocaine hydrochloride 0.1-6.0; dimethyl formamide 10.0-15.0; dimethyl sulphoxide 10.0-15.0; calendula extract 0.1-4.0; Metronidazole 0.1-5.0; polyethylene glycol 400 10.0-15.0; isopropyl alcohol - the rest.

EFFECT: invention provides reduced recovery time of allergic and inflammatory functional condition of skin in an animal.

3 ex

FIELD: chemistry.

SUBSTANCE: benzamide derivatives are presented by the formula [1] or its salt, where Z is -O-, -NR5-, -S-, -SO-; 1 is 0 or 1; m is 0 or 1; R1 is hydrogen atom, C1-6-alkyl group, R2 is hydrogen atom, hydroxylic group, C1-6- alkyl group, carboxyl group, C1-6-alkoxycarbonyl group or -CONR10R11, or R2 and R1 together form =O; R3 is hydrogen atom or C1-6-alkyl group; R4 is hydrogen atom or halogen atom; V is direct bond or -(CR21R22)n-; P1 and P2 rings are the same or different, and each is aromatic or saturated carbocyclic group, or 5-10-member saturated or unsaturated heterocyclic group containing 1-3 heteroatoms selected out of N, O, S.

EFFECT: obtainment of compound with excellent inhibition effect on vanilloid receptor type 1 activity, efficiency in treatment of diseases involving vanilloid receptor type 1 activity.

17 cl, 56 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention belongs to medicine, notably to hepatology, and relates to viral hepatitis A treatment in children with food allergy in acute phase of disease. On admission to hospital patient receives usual complex therapy of hepatitis, complemented with antihistaminic drugs - suprastin or tavegil, and enzymatic drugs - pancreatin or mesym - forte. Suprastin or tavegil is administered ј - 1 tablet after meal two times a day during 7-10 days. Pancreatin or mezym-forte is administered Ѕ-1 tablet 3 times a day during 14-18 days.

EFFECT: method fastens children recovery and reduces frequency of disease residual effects.

1 ex, 6 tbl, 4 dwg

FIELD: chemistry.

SUBSTANCE: present invention relates to phenylalanine derivatives and their pharmaceutically acceptable salts. In formula (1) R11 is a hydroxyl group, an alkoxyl group having 1-6 carbon atoms, which can be substituted with a methoxy group, cycloalkoxyl group having 3-6 carbon atoms, or a benzyloxy group; R12 and R13 each independently represents a hydrogen atom, alkyl group having 1-6 carbon atoms, cycloalkyl group having 3-6 carbon atoms, acetyl group or methyloxycarbonyl group, or N(R12)R13 is a 1-pyrrolidinyl group, 1-piperidinyl group, 4-morpholinyl group; R14 is a methyl group; R1' is a hydrogen atom, fluorine atom; X1 is -CH(R1a)-, -CH(R1a)CH(R1b)-, -CH(R1a)CH(R1b)CH(R1c)-, -N(R1a)CH(R1b)CH(R1c)-, -OCH(R1a)CH(R1b)-, -OCH(R1a)CH(R1b)CH(R1c)- or 1,3-pyrrolidinylene, where R1a, R1b, each independently represents a hydrogen atom or a methyl group, and R1c is a hydrogen atom; Y11 and Y12 represent any of the combinations (CI, Cl), (CI, Me), (CI, F). Invention also relates to phenylalanine derivatives of formulae (2)-(14), given in the formula of invention.

EFFECT: obtaining a pharmaceutical composition having antagonistic effect on α4-integrin, containing a phenylalanine derivative as an active ingredient, a α4-integrin antagonist and a therapeutic agent.

65 cl, 51 tbl, 244 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) capable of bonding with S1P receptor (specifically EDG-6, preferably EDG-1 and EDG-6), its non-toxic water-insoluble salts or its methyl or ethyl ester.

EFFECT: obtaining compounds which can be used in preventing and/or treating graft rejection, graft-versus-host diseases, autoimmune diseases and allergic diseases.

11 cl, 66 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and concerns a complex containing mequitazine, cyclodextrin and a reaction agent where the molar ration within the system mequitazine/cyclodextrin/the reaction agent and mequitazine/the reaction agent is 1/1 - 1/10 and water-dissolution rate of mequitazine being a part of the complex measured for an aqueous solution with mequitazine concentration 2 g/l at 35°C after 15 minutes of stirring, makes more than 50% at pH 9, to a method for preparing said complex and a based pharmaceutical composition.

EFFECT: invention provides improved solubility of mequitazine.

20 cl, 1 dwg, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to tetrahydropyridoindole derivatives of general formula , where R1, R2, R3 and R4 independently represent hydrogen; C1-C5alkyl, which can be optionally substituted and represents trifluoromethyl if C1-C5alkyl is substituted; C1-C3alkoxy or halogen, and R5 is C1-C6alkylcarbonyl, C1-C5alkylcarbamoyl, C1-C5alkoxycarbonyl, C2-C5alkenylcarbonyl, C3-C6cycloalkylcarbonyl, C3-C6cycloalkyl(C1-C3)alkylcarbonyl, C3-C6cycloalkylcarbamoyl, C3-C6cycloalkylthiocarbamoyl, phenylcarbonyl or phenyl(C1-C3)alkylcarbonyl, where the phenyl residue in these two groups contains one, two, three or four substitutes, independently selected from a group comprising C1-C4alkyl, C1-C3alkoxy, halogen, trifluoromethyl and trifluoromethoxy, monosubstituted with a C3-C6cycloalkyl group, or monosubstituted with a phenyl group which in turn is substituted with a C1-C3alkyl group; phenyl(C1-C3)alkoxycarbonyl, phenylcarbamoyl or phenylthiocarbamoyl (where these two groups are optionally independently monosubstituted with a C1-C5alkyl group or halogen atoms); phenyl(C1-C3)alkylcarbamoyl, phenyl(C1-C3)alkylthiocarbamoyl, biphenylcarbamoyl, naphthylcarbonyl, naphthyl(C1-C3)alkylcarbonyl or naphthylcarbamoyl (where the naphthyl residues in these three groups are optionally monosubstituted with substitutes independently selected from a group comprising C1-C3alkyl, C1-C3alkoxy and halogen); fluorenylcarbonyl, optionally substituted with an oxo group, fluorenyl(C1-C3)alkoxycarbonyl; or 5-9-member heteroarylcarbonyl groups containing one or two heteroatoms, independently selected from a group comprising oxygen, nitrogen and sulphur, where the said groups can be substituted with one or two groups independently selected from C1-C3alkyl and halogen, provided that if R1, R2, R3, R4 are hydrogen, R5 is not ethoxycarbonyl or tert-butoxycarbonyl, or salt thereof. The invention also relates to a pharmaceutical composition based on the compound of formula I and to use of the compound in preparing a medicinal agent.

EFFECT: obtaining novel tetrahydropyridoindole derivatives which have CRTH2 receptor antagonistic activity.

14 cl, 14 tbl, 171 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a pharmaceutical product for introduction of allergen that contains high-soluble solid dosage form introduced through tunica mucosa of mouth and containing matrix made by freeze drying from the solution containing 3-6.5 wt % pre-gelled starch and 3-5.5 wt % mannitol, or from the solution containing 2-10 wt % fish gelatine and 1-10 wt % mannitol; and allergen. Besides, invention concerns the method for making the specified product, a multidosage container, a set for allergy treatment, to the method of treating and applying the specified product.

EFFECT: preparation of allergen as a high-soluble uncompacted dosage form which is high-soluble, stable and low-fragile enough.

99 cl, 25 tbl, 1 ex

FIELD: medicine, pharmacology.

SUBSTANCE: method comprise salt-water extraction from raw material using Evans-Cook extraction liquid, mites cultivation during from 3 to 4 months, at temperature 25±2°C and relative air humidity 73±3%, on house dust and bristle. As initial basis, the mix of house dust mites Dermatophagoides farina or Dermatophagoides pternissinus culture and culture medium, including excrements, cast off skins, and food debris, is used. Salt-water extraction from raw material is performed during three days, after mixing it and homogenization with glass powder; the maintained incubation temperature is 2° to 10°C; the extraction material being shaken for 30 minutes three times a day with 1.5 hour intervals. Extraction completed, the supernatant liquor is decanted and centrifuged at 5000 to 6000 rpm for 30-40 minutes, then it is filtered through paper filter; in consequence sterilization through filtering, 3 to 4 months mother solution stabilisation, and bottling are carried out; the finished preparation is produced.

EFFECT: invention provides producing high effective treatment allergen in simplified process technology.

2 ex

FIELD: medicine.

SUBSTANCE: present invention refers to medicine and concerns microparticles containing sphere mainly consisting of cross-linked agarose carbohydrate and allergen covalently bonded with sphere, applied for immune system disturbance treatment. Used allergen is produced of plant pollen, specifically of timothy grass pollen. Application of specified microparticles provides effective treatment for patients suffering from allergy, as well as reduces by-effects of parenteral introduction.

EFFECT: development of effective method of allergy treatment and prevention.

9 cl, 4 dwg, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to conjugates of hydroxyalkyl starch and allergen, in which at least one hydroxyalkyl starch is covalent bonded with allergen for hyposensitisation. Conjugates HAS-allergen provide epitope profile comparable to natural, that enables to increase immunotherapy efficiency.

EFFECT: increasing of immunotherapy efficiency.

14 cl, 5 dwg

FIELD: veterinary microbiology.

SUBSTANCE: the innovation deals with intracutaneous injection of tuberculin at the volume of 0.2 ml followed by analyzing the reaction 72 h later. Animals at increased skin fold by 3 mm and more should be considered to be sick ones. Moreover, tuberculin should be injected at the dosage ranged 0.6-0.8 thousand IU. The innovation excludes the impact upon final result in predicting the factors of tuberculosis-free etiology and provides the liquidation of groundless slaughtering in cattle.

EFFECT: higher accuracy of diagnostics.

2 ex, 2 tbl

FIELD: medicine, in particular production of diagnostic allergen from cockroach.

SUBSTANCE: claimed method includes alkali extraction of raw materials followed by centrifugation, filtering, and sterilizing filtering of target product, wherein as raw material mixture of frozen cockroaches is used. Said mixture is crushed, then ether is added, mixture is shacked, filtered, dried to full ether evaporation, grated to produce powder. In obtained powder ether is added again, powder is dried to full ether evaporation, and alkali extraction is carried out. Extracting material is agitated and for 3 days is shacked three times daily for 30 min with 1.5 h interval and stored for these intervals at 2-10°C. After extraction supernatant is discharged, centrifuged, and after sterilizing filtering sterile allergen solution is held for 1-3 months at 2-10°C.

EFFECT: high effective preparation for diagnosis of diseases associated with sensitizing to cockroach.

1 ex

FIELD: medicine.

SUBSTANCE: method involves applying alkaline extraction from raw material. Daphnias are used as initial raw material, preliminary degreased with ethylic ether, dried up and crushed up to powder condition. The fat-free powder is extracted with 0.1 mole/l sodium hydroxide solution during 3 days at temperature of 4-8°C. Supernatant liquid is poured out after having finished extracting and protein is sedimented from alkaline extract with sodium benzoate as follows: 20 g of sodium benzoate is available in 1 l of alkaline extract, alkaline extract рН is reduced to 3.7. Sedimented benzoic acid is precipitated with the adsorbed allergen by centrifuging within 5 min at 2000 rpm. Allergen desorbed with benzoic acids by adding to acetone deposit. The mixture is stirred to completely dissolve benzoic acid and then it is places for 12-18 h into refrigerator at -20°С temperature. The solution is filtered, waiting 18-20 hours for full evaporation of acetone traces. Allergen powder is extracted during 3 days. Allergenic extract is centrifuged at 5000-6000 rpm within 30-40 minutes with sterilizing filtration following until ready form of diagnostic allergen being obtained. The produced preparation has been studied according to methodical instructions to primary experimentally-clinical approbation of new forms of allergens.

EFFECT: reduced risk of adverse side effects; high specific activity; no animal sensitization when given in the diagnostic doses.

FIELD: medicine, allergology, toxins, pharmacy.

SUBSTANCE: invention relates to recombinant allergens of insect venom and to specific methods for their preparing, in particular, antigen 5 of wasp venom allergen. Recombinant antigen 5 is prepared in bacterial cells as insoluble aggregates followed by their denaturation and transfer to a soluble monomeric allergen. Transfer is carried out by dialysis using acid buffer solution (pH = 3.5-6.5) that can comprise guanidine hydrochloride, or by using a cysteine-containing solvent. Based on describes methods the practically pure recombinant antigen 5 of wasp venom allergen is isolated and used in pharmaceutical composition for hyposensibilization of body to wasp venom allergen. Invention provides preparing protein with reduced reaction capability JgE owing to it can be used in immunotherapy in treatment of allergy.

EFFECT: improved preparing method, valuable properties of allergen.

8 cl, 1 dwg

FIELD: medicine, immunology, allergology.

SUBSTANCE: one should detect the parameters of immune state and objective anamnesis, before carrying out specific immunotherapy (SIT) with allergens one should detect IgM level (g/l), the quantity of monocytes (Mon), lymphocytes (Lymph) in total blood analysis in %, the quantity of B lymphocytes in % (CD19), immunoregulatory index (IRI) (CD4/CD8), phagocytic value in % (PhV), IgE serumal level in IU/ml, the quantity of points in evaluating accompanying nonallergic anamnesis (Point) {one point in case of one chronic disease, 2 points in case of two, etc.}, then one should calculate the changes in immunity parameters on the 7th d of SIT-therapy, obtained values should be applied in the following equation of regression (Y= -195.4 + 117.3·IgM + 10.8·Mon - 0.35·IgE - 17.1·Point + 7.8·Dlymph + 20.4·Dmon + 3·Dbl + 22.8·Diri) and calculating the possibility of complications it is necessary to perform by the following formula: P = 100/(1+Exp(-Y)).

EFFECT: higher accuracy of prediction and improved quality of therapy.

3 ex

FIELD: medicine.

SUBSTANCE: allergen is taken as aqueous salt solution of protein polysaccharide complex of 10000 PNU activity produced by extracting dry degreased gnat of Aedes aegypti with alkaline buffer solution at pH of 8.0-8.2 with following cleaning as means for specific immunotherapy means applicable to allergic disease patients having sensitization to gnat stings. Method involves applying allergen of 10000 PNU concentration in 10-fold dilution introduced to a patient beginning from a dose of 0.2 ml with 1-2 days long pause. Supporting doses of the allergen are administered to the patients before gnat flight season with 10-12 days long pauses.

EFFECT: high effectiveness of the allergen and treatment method.

3 cl

FIELD: medicine.

SUBSTANCE: persistent wound and trophic ulcer healing in the patients suffering from pancreatic diabetes is ensured by application of medicinal leeches on the wound surface 2-3 times a day followed by application of ointment Piyavit within preparation of the wound surface. The procedure follows until the entire ulcerous bottom is filled with granulation tissue. Then skin flap pre-cured with the ointment Piyavit is transplanted. From the first postoperative days, medicinal leeches are applied on the skin flap in number of 1-3 pieces per a session for course 8-10 days. Then the operative wound is closed with a sterile dressing applied over bandage with ointment Piyavit. The whole therapeutic course involves introduction of capsulated Piyavit in dose 300 mg 2 times a day.

EFFECT: reduced intensity of inflammatory reaction; accelerated start of wound healing with decreased area and reduced recurrence.

2 ex

Up!